Welcome to the healthcare professionals section
In this section, you will find information on RenehaVis™ and its use in knee and hip osteoarthitis (OA).
We have included RenehaVis™ prescribing information, clinical references, a video demonstrating the mechanism of action of RenehaVis™ and other useful information.
If you require further assistance, please contact us.
A clinical study was conducted studying the effects of RenehaVis™ versus a high molecular weight HA, a low molecular weight HA and placebo. This double blind, placebo controlled, study in Canada showed that patients administered with RenehaVis™ had lower pain scores when walking and at rest compared to the other three arms in the study, notably in a shorter period of time.
RenehaVis patients had the lowest pain score after the 2nd injection and this was maintained for up to 16 weeks.
An innovative product for knee and hip OA, RenehaVis™ is the only product on the market that contains 2 Hyaluronic Acids in 1 syringe for a sequential injection.
Chamber 1 contains: Low molecular weight HA – High concentration
Chamber 2 contains: High molecular weight HA – Low concentration
RenehaVis™ offers both patients and doctors the DMC concept: Dual Molecular weight and Concentration concept in a single syringe.
All viscosupplementation products try to help knee OA patients to regain a healthy physiological state of the knee. Low molecular weight Hyaluronic Acid (HA) is known to be able to act as a lubricant in the synovial joint whereas high molecular Hyaluronic Acid (HA) is known for its ability to absorb shocks experienced by the joint.
Low molecular weight HA has 2 other functions:
It diffuses through the cartilage to protect the chondrocytes (note: a molecule which helps create endogenous HA and proteoglycans) which are commonly destroyed in knee OA patients. This is termed as the "CAGING EFFECT".
It diffuses to the synoviocytes of the synovial membrane to stimulate production of endogenous HA. This action is known as the MECHANOSENSITIVE EFFECT.
This is why RenehaVis™ has a concentration of low molecular weight HA – to achieve these 3 criteria needed in an OA knee.
The high molecular weight Hyaluronic Acid (HA) is at a lower concentration as it only has 1 function (i.e., shock absorption) as it only has to maintain this function whereas a higher concentration of the low molecular weight HA is provided.
Trained Healthcare Practitioners can assess when patients will require re-administration of RenehaVis™ as it depends on the current condition of the disease.
RenehaVis™ is administered via an intra-articular injection and should only be made by a Healthcare Professional trained in the technique. Care should always be taken to ensure that entry into the synovial capsule is obtained. There are various techniques to do an intra-articular injection. Administration depends greatly on what the patient and the administrator (trained healthcare practitioner) are most comfortable with. Ultrasound - or fluoroscopy - guided injections are recommended especially for intra-articular injection into the hip joint.
There were no serious adverse events during the clinical study. Non-serious adverse events included pain and local swelling at the injection site (21%), erythema at the injection site (12%), and stiffness in the index knee (7%) amongst all groups.